Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?
Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...
Hosted on MSN1mon
FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment
The Food and Drug Administration approved Johnson & Johnson's nasal spray ... first-ever stand-alone therapy for treatment-resistant depression, which is when trying at least two standard ...
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar ...
Can AI Unlock New Treatment Possibilities For Inflammatory Bowel Disease? How Johnson & Johnson Is Leading The Way
Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...
Johnson & Johnson (NYSE:JNJ) Goes to Court for Third Time over $10B Talc Bankruptcy Plan
Johnson & Johnson (JNJ) begins on Tuesday its third attempt to push through a multi-billion-dollar settlement relating to ...
Forbes26d
Atopic Dermatitis Affects Millions, And Johnson & Johnson Is Committed To Addressing The Unmet Needs Of Patients
For people with AD, Johnson & Johnson's research offers hope ... “Many patients with AD have higher rates of depression, anxiety, stress and suicide,” she says. Existing treatments for AD ...